ACS Medicinal Chemistry Letters
Letter
(14) Chang, C. J.; Hung, M.-C. The Role of EZH2 in Tumour
Progression. Br. J. Cancer 2012, 106, 243−247.
REFERENCES
■
(1) Kouzarides, T. Chromatin Modifications and Their Function. Cell
2007, 128, 693−705.
(2) Jones, P. A.; Baylin, S. B. The Epigenomics of Cancer. Cell 2007,
128, 683−692.
(3) Wilson, C. B.; Rowell, E.; Sekimata, M. Epigenetic Control of T-
Helper-Cell Differentiation. Nat. Rev. Immunol. 2009, 9, 91−105.
(4) Tsankova, N.; Renthal, W.; Kumar, A.; Nestler, E. J. Epigenetic
Regulation in Psychiatric Disorders. Nat. Rev. Neurosci. 2007, 8, 355−
367.
(5) Simon, J. A.; Lange, C. A. Roles of the EZH2 Histone
Methyltransferase in Cancer Epigenetics. Epigenetics Mutat. Res. 2008,
647, 21−29.
(6) Varambally, S.; Dhanasekaran, S. M.; Zhou, M.; Barrette, T. R.;
Kumar-Sinha, C.; Sanda, M. G.; Ghosh, D.; Pienta, K. J.; Sewalt, R. G. A.
B.; Otte, A. P.; Rubin, M. A.; Chinnaiyan, A. M. The Polycomb Group
Protein EZH2 is Involved in Progression of Prostate Cancer. Nature
2002, 419, 624−629.
(15) McCabe, M. T.; Graves, A. P.; Ganji, G.; Diaz, E.; Halsey, W. S.;
Jiang, Y.; Smitheman, K. N.; Ott, H. M.; Pappalardi, M. B.; Allen, K. E.;
Chen, S. B.; Della Pietra, A., III; Dul, E.; Hughes, A. M.; Gilbert, S. A.;
Thrall, S. H.; Tummino, P. J.; Kruger, R. G.; Brandt, M.; Schwartz, B.;
Creasy, C. L. Mutation of A677 in Histone Methyltransferase EZH2 in
Human B-Cell Lymphoma Promotes Hypertrimethylation of Histone
H3 on Lysine 27 (H3K27). Proc. Natl. Acad. Sci. 2012, 109, 2989−2994.
(16) Allan, M.; Manku, S.; Therrien, E.; Nguyen, N.; Styhler, S.;
Robert, M.-F.; Goulet, A.-C.; Petschner, A. J.; Rahil, G.; MacLeod, A. R.;
́
Deziel, R.; Besterman, J. M.; Nguyen, H.; Wahhab, A. N-Benzyl-1-
Heteroaryl-3-(trifluoromethyl)-1H-Pyrazole-5-Carboxamides as Inhib-
itors of Co-activator Associated Arginine Methyltransferase 1
(CARM1). Bioorg. Med. Chem. Lett. 2009, 19, 1218−1223.
(17) Liu, F.; Chen, X.; Allali-Hassani, A.; Quinn, A. M.; Wasney, G. A.;
Dong, A.; Barsyte, D.; Kozieradzki, I.; Senisterra, G.; Chau, I.;
Siarheyeva, A.; Kireev, D. B.; Jadhav, A.; Herold, J. M.; Frye, S. V.;
Arrowsmith, C. H.; Brown, P. J.; Simeonov, A.; Vedadi, M.; Jin, J.
Discovery of a 2,4-Diamino-7-Aminoalkoxyquinazoline as a Potent and
Selective Inhibitor of Histone Lysine Methyltransferase G9a. J. Med.
Chem. 2009, 52, 7950−7953.
(18) Liu, F.; Chen, X.; Allali-Hassani, A.; Quinn, A. M.; Wigle, T. J.;
Wasney, G. A.; Dong, A.; Senisterra, G.; Chau, I.; Siarheyeva, A.; Norris,
J. L.; Kireev, D. B.; Jadhav, A.; Herold, J. M.; Janzen, W. P.; Arrowsmith,
C. H.; Frye, S. V.; Brown, P. J.; Simeonov, A.; Vedadi, M.; Jin, J. Protein
Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and
Structure Activity Relationships of 2,4-Diamino-7-Aminoalkoxy-Quina-
zolines. J. Med. Chem. 2010, 53, 5844−5857.
(7) Kleer, C. G.; Cao, Q.; Varambally, S.; Shen, R.; Ota, I.; Tomlins, S.
A.; Ghosh, D.; Sewalt, R. G. A. B.; Otte, A. P.; Hayes, D. F.; Sabel, M. S.;
Livant, D.; Weiss, S. J.; Rubin, M. A.; Chinnaiyan, A. M. EZH2 is a
Marker of Aggressive Breast Cancer and Promotes Neoplastic
Transformation of Breast Epithelial Cells. Proc. Natl. Acad. Sci. 2003,
100, 11606−11611.
(8) Wagener, N.; Macher-Goeppinger, S.; Pritsch, M.; Husing, J.;
̈
Hoppe-Seyler, K.; Schirmacher, P.; Pfitzenmaier, J.; Haferkamp, A.;
Hoppe-Seyler, F.; Hohenfellner, M. Enhancer of Zeste Homolog 2
(EZH2) Expression is an Independent Prognostic Factor in Renal Cell
Carcinoma. BMC Cancer 2010, 10, 524.
(19) Daigle, S. R.; Olhava, E. J.; Therkelsen, C. A.; Majer, C. R.;
Sneeringer, C. J.; Song, J.; Johnston, L. D.; Porter Scott, M.; Smith, J. J.;
Xiao, Y.; Jin, L.; Kuntz, K. W.; Chesworth, R.; Moyer, M. P.; Bernt, K.
M.; Tseng, J.-C.; Kung, A. L.; Armstrong, S. A.; Copeland, R. A.; Richon,
V. M.; Pollock, R. M. Selective Killing of Mixed Lineage Leukemia Cells
by a Potent Small-Molecule DOT1L Inhibitor. Cancer Cell 2011, 20,
53−65.
(20) Yao, Y.; Chen, P.; Diao, J.; Cheng, G.; Deng, L.; Anglin, J. L.;
Prasad, B. V. V; Song, Y. Selective Inhibitors of Histone Methyltransfer-
ase DOT1L: Design, Synthesis, and Crystallographic Studies. J. Am.
Chem. Soc. 2011, 133, 16746−16749.
(9) Takawa, M.; Masuda, K.; Kunizaki, M.; Daigo, Y.; Takagi, K.; Iwai,
Y.; Cho, H.-S.; Toyokawa, G.; Yamane, Y.; Maejima, K.; Field, H. I.;
Kobayashi, T.; Akasu, T.; Sugiyama, M.; Tsuchiya, E.; Atomi, Y.; Ponder,
B. A. J.; Nakamura, Y.; Hamamoto, R. Validation of the Histone
Methyltransferase EZH2 as a Therapeutic Target for Various Types of
Human Cancer and as a Prognostic Marker. Cancer Sci. 2011, 102,
1298−1305.
(10) Morin, R. D.; Johnson, N. A.; Severson, T. M.; Mungall, A. J.; An,
J.; Goya, R.; Paul, J. E.; Boyle, M.; Woolcock, B. W.; Kuchenbauer, F.;
Yap, D.; Humphries, R. K.; Griffith, O. L.; Shah, S.; Zhu, H.; Kimbara,
M.; Shashkin, P.; Charlot, J. F.; Tcherpakov, M.; Corbett, R.; Tam, A.;
Varhol, R.; Smailus, D.; Moksa, M.; Zhao, Y.; Delaney, A.; Qian, H.;
Birol, I.; Schein, J.; Moore, R.; Holt, R.; Horsman, D. E.; Connors, J. M.;
Jones, S.; Aparicio, S.; Hirst, M.; Gascoyne, R. D.; Marra, M. A. Somatic
Mutations Altering EZH2 (Tyr641) in Follicular and Diffuse Large B-
Cell Lymphomas of Germinal-Center Origin. Nat. Genet. 2010, 42,
181−185.
(11) Morin, R. D.; Mendez-Lago, M.; Mungall, A. J.; Goya, R.;
Mungall, K. L.; Corbett, R. D.; Johnson, N. A.; Severson, T. M.; Chiu, R.;
Field, M.; Jackman, S.; Krzywinski, M.; Scott, D. W.; Trinh, D. L.;
Tamura-Wells, J.; Li, S.; Firme, M. R.; Rogic, S.; Griffith, M.; Chan, S.;
Yakovenko, O.; Meyer, I. M.; Zhao, E. Y.; Smailus, D.; Moksa, M.;
Chittaranjan, S.; Rimsza, L.; Brooks-Wilson, A.; Spinelli, J. J.; Ben-
Neriah, S.; Meissner, B.; Woolcock, B.; Boyle, M.; McDonald, H.; Tam,
A.; Zhao, Y.; Delaney, A.; Zeng, T.; Tse, K.; Butterfield, Y.; Birol, I.; Holt,
R.; Schein, J.; Horsman, D. E.; Moore, R.; Jones, S. J. M.; Connors, J. M.;
Hirst, M.; Gascoyne, R. D.; Marra, M. A. Frequent Mutation of Histone-
Modifying Genes in Non-Hodgkin Lymphoma. Nature 2011, 476, 298−
303.
(12) Pasqualucci, L.; Trifonov, V.; Fabbri, G.; Ma, J.; Rossi, D.;
Chiarenza, A.; Wells, V. A.; Grunn, A.; Messina, M.; Elliot, O.; Chan, J.;
Bhagat, G.; Chadburn, A.; Gaidano, G.; Mullighan, C. G.; Raul Rabadan,
R.; Riccardo Dalla-Favera, R. Analysis of the Coding Genome of Diffuse
Large B-Cell Lymphoma. Nat. Genet. 2011, 43, 830−837.
(21) Ferguson, A. D.; Larsen, N. A.; Howard, T.; Pollard, H.; Green, I.;
Grande, C.; Cheung, T.; Garcia-Arenas, R.; Cowen, S.; Wu, J.; Godin, R.;
Chen, H.; Keen, N. Structural Basis of Substrate Methylation and
Inhibition of SMYD2. Structure 2011, 19, 1262−1273.
(22) Vedadi, M.; Barsyte-Lovejoy, D.; Liu, F.; Rival-Gervier, S.; Allali-
Hassani, A.; Labrie, V.; Wigle, T. J.; DiMaggio, P. A.; Wasney, G. A.;
Siarheyeva, A.; Dong, A.; Tempel, W.; Wang, S-C.; Chen, X.; Chau, I.;
Mangano, T. J.; Huang, X-P.; Simpson, C. D.; Pattenden, S. G.; Norris, J.
G.; Kireev, D. B.; Tripathy, A.; Edwards, A.; Roth, B. L.; Janzen, W. P.;
Garcia, B. A.; Petronis, A.; Ellis, J.; Brown, P. J.; Frye, S. V.; Arrowsmith,
C. H.; Jin, J. A Chemical Probe Selectively Inhibits G9a and GLP
Methyltransferase Activity in Cells. Nat. Chem. Biol. 2011, 7, 566−574.
(23) McCabe, M. T.; Ott, H. M.; Ganji, G.; Korenchuk S.; Thompson,
C. S.; Van Aller, G. S.; Liu, Y.; Graves A. P.; Della Pietra III, A.; Diaz, E.;
LaFrance, L. V.; Mellinger, M.; Duquenne, C.; Tian, X.; Kruger, R. G.;
McHugh, C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.;
Tummino, P. T.; Creasy, C. L. Inhibition of EZH2Methyltransferase
Activity as a Therapeutic Strategy for Diffuse Large B-Cell Lymphoma
with EZH2 Activating Mutations. Nature, published online October 10,
2012; DOI: 10.1038/nature11606.
(24) Knutson, S. K.; Wigle, T. J.; Warholic, N. M.; Sneeringer, C. J.;
Allain, C. J.; Klaus, C. R.; Sacks, J. D.; Raimondi, A.; Majer, C. R.; Song,
J.; Scott, M. P.; Jin, L.; Smith, J. J.; Olhava, E. J.; Chesworth, R.; Moyer,
M. P.; Richon, V. M.; Copeland, R. A.; Keilhack, H.; Pollock, R. M.;
Kuntz, K. W. A Selective Inhibitor of EZH2 blocks H3K27 methylation
and kills mutant lymphoma cells. Nat. Chem. Biol., published online
September 30, 2012; DOI: 10.1038/NCHEMBIO.1084.
(13) Ernst, T.; Chase, A. J.; Score, J.; Hidalgo-Curtis, C. E.; Bryant, C.;
Jones, A. V.; Waghorn, K.; Zoi, K.; Ross, F. M.; Reiter, A.; Hochhaus, A.;
Drexler, H. G.; Duncombe, A.; Cervantes, F.; Oscier, D.; Boultwood, J.;
Grand, F. H.; Cross, N. C. P. Inactivating Mutations of the Histone
Methyltransferase Gene EZH2 in Myeloid Disorders. Nat. Genet. 2010,
42, 722−726.
(25) Miranda, T. B.; Cortez, C. C.; Yoo, C. B.; Liang, G.; Abe, M.;
Kelly, T. K.; Marquez, V. E.; Jones, P. A. DZNep is a Global Histone
E
dx.doi.org/10.1021/ml3003346 | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX